Majid Jaberi-Douraki, PhD -Kansas State University and Shahzad Raza, MD – Cleveland Clinic
This study analyzed data from the FDA Adverse Event Reporting System (FAERS) to evaluate global disparities in multiple myeloma (MM) and drug toxicity trends. The analysis of adverse events (AEs) associated with FDA-approved MM drugs revealed variations in AE incidence based on age, sex, and geographical regions. Disparities were observed in specific AEs such as cardiotoxicities, vascular toxicities, nephrotoxicity, peripheral neuropathies, secondary neoplasms, and respiratory tract neoplasms, which may be influenced by factors like genetics, dosing/regimen, comorbidities, age, and sex. These findings highlight the importance of further investigation to improve patient care, reduce AEs, minimize mortality, and optimize healthcare resource allocation in MM treatment.